HUE047547T2 - Ciklobenzaprin-hidroklorid és mannit eutektikus formulációi - Google Patents
Ciklobenzaprin-hidroklorid és mannit eutektikus formulációiInfo
- Publication number
- HUE047547T2 HUE047547T2 HUE14762323A HUE14762323A HUE047547T2 HU E047547 T2 HUE047547 T2 HU E047547T2 HU E14762323 A HUE14762323 A HU E14762323A HU E14762323 A HUE14762323 A HU E14762323A HU E047547 T2 HUE047547 T2 HU E047547T2
- Authority
- HU
- Hungary
- Prior art keywords
- mannitol
- cyclobenzaprine hydrochloride
- eutectic
- eutectic formulations
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361792757P | 2013-03-15 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE047547T2 true HUE047547T2 (hu) | 2020-04-28 |
Family
ID=51538423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE14762323A HUE047547T2 (hu) | 2013-03-15 | 2014-03-14 | Ciklobenzaprin-hidroklorid és mannit eutektikus formulációi |
Country Status (27)
Country | Link |
---|---|
US (9) | US9636408B2 (hu) |
EP (2) | EP2968992B8 (hu) |
JP (5) | JP6310542B2 (hu) |
CN (2) | CN110152005B (hu) |
AU (1) | AU2014233277B2 (hu) |
BR (1) | BR112015022095B1 (hu) |
CA (2) | CA3119755C (hu) |
CY (1) | CY1122740T1 (hu) |
DK (2) | DK2968992T3 (hu) |
ES (1) | ES2769879T3 (hu) |
FI (1) | FI3650081T3 (hu) |
HK (1) | HK1218727A1 (hu) |
HR (2) | HRP20240648T1 (hu) |
HU (1) | HUE047547T2 (hu) |
IL (1) | IL241353B (hu) |
LT (2) | LT2968992T (hu) |
MX (2) | MX370021B (hu) |
MY (1) | MY196014A (hu) |
NZ (1) | NZ631152A (hu) |
PL (2) | PL3650081T3 (hu) |
PT (2) | PT2968992T (hu) |
RS (2) | RS60015B1 (hu) |
SA (1) | SA515361124B1 (hu) |
SG (2) | SG10201707528WA (hu) |
SI (2) | SI2968992T1 (hu) |
TW (2) | TWI661825B (hu) |
WO (1) | WO2014145156A2 (hu) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2459064A1 (en) | 2009-07-27 | 2012-06-06 | Cardiac Pacemakers, Inc. | Medical device for treating heart failure through blood volume redistribution |
NO2501234T3 (hu) | 2009-11-20 | 2018-02-10 | ||
US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
MX2021005317A (es) * | 2012-06-15 | 2022-12-16 | Tonix Pharmaceuticals Inc | Composiciones y métodos para absorción transmucosa. |
CN110152005B (zh) | 2013-03-15 | 2023-08-04 | 通尼克斯制药控股有限公司 | 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂 |
RU2696578C1 (ru) | 2014-02-05 | 2019-08-05 | Мерк Шарп И Доум Корп. | Технология приготовления таблеток для cgrp-активных соединений |
JP6614724B2 (ja) * | 2014-09-18 | 2019-12-04 | トニックス ファーマ ホールディングス リミテッド | シクロベンザプリン塩酸塩の共融製剤 |
CN118267382A (zh) * | 2017-12-11 | 2024-07-02 | 通尼克斯制药控股有限公司 | 用于痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗 |
WO2020039256A1 (en) | 2018-08-20 | 2020-02-27 | Tonix Pharma Holdings Limited | Methods of treating acute stress disorder and posttraumatic stress disorder |
NL2023661B1 (en) | 2019-08-19 | 2021-04-21 | Seranovo Holding B V | Pharmaceutical Eutectic Salt Formulation |
JP7088153B2 (ja) * | 2019-09-19 | 2022-06-21 | カシオ計算機株式会社 | Cap(周期性脳波活動)検出装置、cap(周期性脳波活動)検出方法及びプログラム |
EP4132648A1 (en) * | 2020-04-08 | 2023-02-15 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for sexual dysfunction |
CA3190176A1 (en) | 2020-07-29 | 2022-02-03 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
WO2022109218A1 (en) * | 2020-11-20 | 2022-05-27 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for alcohol use disorder |
CN116940340A (zh) | 2020-12-07 | 2023-10-24 | 通尼克斯医药控股公司 | 纤维肌痛的环苯扎林治疗 |
MX2023007575A (es) | 2020-12-22 | 2023-09-21 | Allergan Pharmaceuticals Int Ltd | Tratamiento de la migraña. |
WO2022170107A2 (en) | 2021-02-04 | 2022-08-11 | Tonix Pharmaceuticals Holding Corp. | An improved method of assessing clinical response in the treatment of ptsd symptoms |
CN113116843A (zh) * | 2021-05-11 | 2021-07-16 | 福建海西新药创制有限公司 | 一种含有缬沙坦的药物组合物及其制备方法 |
EP4412602A1 (en) | 2021-10-06 | 2024-08-14 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients |
WO2023250036A1 (en) | 2022-06-21 | 2023-12-28 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for post-acute sequelae of (sars)-cov-2 infection (pasc) |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4968507A (en) | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
IL72684A (en) | 1984-08-14 | 1989-02-28 | Israel State | Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs |
JP2551754B2 (ja) * | 1986-04-17 | 1996-11-06 | 内橋エステック 株式会社 | ペレツト型温度ヒユ−ズ |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
FR2635461B1 (fr) | 1988-08-18 | 1992-01-17 | Adir | Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
SG47101A1 (en) | 1992-07-31 | 1998-03-20 | Us Bioscience | Crystalline amifostine compositions and methods for the preparation and use of same |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
EP0693924B2 (en) | 1993-02-22 | 2008-04-09 | Abraxis BioScience, Inc. | Methods for (in vivo) delivery of biologics and compositions useful therefor |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
DE4439858A1 (de) | 1994-11-08 | 1996-05-09 | Merck Patent Gmbh | Durch Co-Sprühtrocknung erhältliche Polyol-Zusammensetzung |
US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
US6649186B1 (en) * | 1996-09-20 | 2003-11-18 | Ethypharm | Effervescent granules and methods for their preparation |
US20030077227A1 (en) | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
WO1999018937A1 (en) | 1997-10-16 | 1999-04-22 | Merck & Co., Inc. | New cyclobenzaprine composition |
ATE229326T1 (de) | 1998-05-14 | 2002-12-15 | Alza Corp | Therapie von depressionen |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
CA2380373A1 (en) | 1999-08-13 | 2001-02-22 | Seth Lederman | Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof |
BR0013017A (pt) * | 1999-08-13 | 2002-04-16 | Vela Pharmaceuticals Inc | Usos de composições para o tratamento ou prevenção dos distúrbios do sono usando doses muito baixas de ciclobenzaprina |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
WO2001089476A1 (en) | 2000-05-19 | 2001-11-29 | Npd Llc | Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements |
ATE427745T1 (de) | 2001-11-05 | 2009-04-15 | Krele Pharmaceuticals Llc | Zusammensetzungen und verfahren zur erhíhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus |
US7105486B2 (en) | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
US7659253B2 (en) | 2002-02-22 | 2010-02-09 | Shire Llc | Abuse-resistant amphetamine prodrugs |
US7700561B2 (en) | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
US7038085B2 (en) | 2002-10-25 | 2006-05-02 | Collegium Pharmaceutical, Inc. | Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof |
CN103405405A (zh) | 2002-12-09 | 2013-11-27 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
US20050059656A1 (en) | 2003-04-07 | 2005-03-17 | Cornell Research Foundation, Inc. | Compositions and methods for protecting against mitochondria component-mediated pathology |
JP4898445B2 (ja) | 2003-05-29 | 2012-03-14 | シャイア エルエルシー | 乱用抵抗性アンフェタミン化合物類 |
CA2543710A1 (en) | 2003-11-03 | 2005-05-12 | Warner-Lambert Company Llc | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders |
US20050143350A1 (en) | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
JP2007516259A (ja) * | 2003-12-09 | 2007-06-21 | メッドクリスタルフォームズ、エルエルシー | 活性剤との混合相共結晶の調製方法 |
US7658945B2 (en) | 2004-02-17 | 2010-02-09 | Transcept Pharmaceuticals, Inc. | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
US8216610B2 (en) * | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
US20070196364A1 (en) | 2004-07-27 | 2007-08-23 | Human Genome Sciences, Inc. | Pharmaceutical Formulation and Process |
TWI377913B (en) | 2005-01-24 | 2012-12-01 | Food Science Co Ltd B | Eutectic crystalline sugar alcohol and manufacturing method thereof |
US7532935B2 (en) | 2005-07-29 | 2009-05-12 | Cyberonics, Inc. | Selective neurostimulation for treating mood disorders |
US7994220B2 (en) | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
US20080146672A1 (en) * | 2006-12-08 | 2008-06-19 | Denton Marcia Marye | Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue |
ES2431570T3 (es) | 2007-05-07 | 2013-11-27 | Chelsea Therapeutics, Inc. | Droxidopa y composición farmacéutica de la misma para el tratamiento de los trastornos por déficit de atención |
CA2690737A1 (en) | 2007-06-22 | 2008-12-31 | Merck Sharp & Dohme Corp. | 6.5-pyrrolopiperidine tachykinin receptor antagonists |
CA2707858A1 (en) | 2007-07-23 | 2009-01-29 | Synosia Therapeutics, Inc. | Treatment of post-traumatic stress disorder |
US20090060983A1 (en) | 2007-08-30 | 2009-03-05 | Bunick Frank J | Method And Composition For Making An Orally Disintegrating Dosage Form |
HUE043897T2 (hu) * | 2007-09-25 | 2019-09-30 | Solubest Ltd | Lipofil hatóanyagot tartalmazó készítmények és eljárás elõállításukra |
EP2203158A4 (en) | 2007-10-30 | 2012-12-26 | Reddys Lab Ltd Dr | PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE |
US20090148532A1 (en) | 2007-12-06 | 2009-06-11 | Venkatesh Gopi M | Preparation of controlled release skeletal muscle relaxant dosage forms |
CA2905541C (en) | 2008-01-09 | 2020-02-11 | Charleston Laboratories, Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
EP2244679A4 (en) * | 2008-02-08 | 2013-10-09 | Qps Llc | NON-POLYMERIC COMPOSITIONS FOR CONTROLLED MEDICINAL PRODUCTION |
US9314469B2 (en) | 2008-05-05 | 2016-04-19 | Tonix Pharma Holdings Limited | Method for treating neurocognitive dysfunction |
JP5380909B2 (ja) | 2008-05-30 | 2014-01-08 | 株式会社ブリヂストン | 金型及び樹脂発泡成形品の成形方法 |
US20100266682A1 (en) | 2008-12-10 | 2010-10-21 | Nipun Davar | Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same |
US20100247586A1 (en) | 2009-03-27 | 2010-09-30 | Andreas Hugerth | Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties |
EP2233134A1 (en) | 2009-03-27 | 2010-09-29 | McNeil AB | Multi-portion intra-oral dosage form with organoleptic properties |
US8871263B2 (en) | 2009-09-24 | 2014-10-28 | Mcneil-Ppc, Inc. | Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder |
NO2501234T3 (hu) | 2009-11-20 | 2018-02-10 | ||
US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
US20130165511A1 (en) | 2010-09-01 | 2013-06-27 | TONIX Pharmaceuticals Holding Corp | Treatment for cocaine addiction |
US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
ITMI20110558A1 (it) | 2011-04-06 | 2012-10-07 | Campiglio Consulting Srl | Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale |
AU2012289968B2 (en) | 2011-08-04 | 2014-01-16 | Omeros Corporation | Stable anti-inflammatory solutions for injection |
MX2021005317A (es) | 2012-06-15 | 2022-12-16 | Tonix Pharmaceuticals Inc | Composiciones y métodos para absorción transmucosa. |
CN110152005B (zh) | 2013-03-15 | 2023-08-04 | 通尼克斯制药控股有限公司 | 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂 |
JP6614724B2 (ja) * | 2014-09-18 | 2019-12-04 | トニックス ファーマ ホールディングス リミテッド | シクロベンザプリン塩酸塩の共融製剤 |
WO2020039256A1 (en) | 2018-08-20 | 2020-02-27 | Tonix Pharma Holdings Limited | Methods of treating acute stress disorder and posttraumatic stress disorder |
-
2014
- 2014-03-14 CN CN201910263541.6A patent/CN110152005B/zh active Active
- 2014-03-14 DK DK14762323.5T patent/DK2968992T3/da active
- 2014-03-14 CA CA3119755A patent/CA3119755C/en active Active
- 2014-03-14 MX MX2015012622A patent/MX370021B/es active IP Right Grant
- 2014-03-14 SG SG10201707528WA patent/SG10201707528WA/en unknown
- 2014-03-14 EP EP14762323.5A patent/EP2968992B8/en active Active
- 2014-03-14 MY MYPI2015703142A patent/MY196014A/en unknown
- 2014-03-14 US US14/214,433 patent/US9636408B2/en active Active
- 2014-03-14 US US14/776,624 patent/US10117936B2/en active Active
- 2014-03-14 HR HRP20240648TT patent/HRP20240648T1/hr unknown
- 2014-03-14 TW TW103109816A patent/TWI661825B/zh active
- 2014-03-14 PT PT147623235T patent/PT2968992T/pt unknown
- 2014-03-14 PL PL19214535.7T patent/PL3650081T3/pl unknown
- 2014-03-14 PL PL14762323T patent/PL2968992T3/pl unknown
- 2014-03-14 TW TW108114946A patent/TWI740136B/zh active
- 2014-03-14 AU AU2014233277A patent/AU2014233277B2/en active Active
- 2014-03-14 NZ NZ631152A patent/NZ631152A/en unknown
- 2014-03-14 SI SI201431487T patent/SI2968992T1/sl unknown
- 2014-03-14 SI SI201432074T patent/SI3650081T1/sl unknown
- 2014-03-14 EP EP19214535.7A patent/EP3650081B1/en active Active
- 2014-03-14 CA CA2904812A patent/CA2904812C/en active Active
- 2014-03-14 JP JP2016503239A patent/JP6310542B2/ja active Active
- 2014-03-14 LT LTEP14762323.5T patent/LT2968992T/lt unknown
- 2014-03-14 FI FIEP19214535.7T patent/FI3650081T3/fi active
- 2014-03-14 ES ES14762323T patent/ES2769879T3/es active Active
- 2014-03-14 WO PCT/US2014/029872 patent/WO2014145156A2/en active Application Filing
- 2014-03-14 BR BR112015022095-9A patent/BR112015022095B1/pt active IP Right Grant
- 2014-03-14 DK DK19214535.7T patent/DK3650081T3/da active
- 2014-03-14 RS RS20200094A patent/RS60015B1/sr unknown
- 2014-03-14 PT PT192145357T patent/PT3650081T/pt unknown
- 2014-03-14 HU HUE14762323A patent/HUE047547T2/hu unknown
- 2014-03-14 LT LTEP19214535.7T patent/LT3650081T/lt unknown
- 2014-03-14 SG SG11201507124XA patent/SG11201507124XA/en unknown
- 2014-03-14 RS RS20240532A patent/RS65500B1/sr unknown
- 2014-03-14 CN CN201480024011.1A patent/CN105142730B/zh active Active
-
2015
- 2015-09-09 IL IL24135315A patent/IL241353B/en active IP Right Grant
- 2015-09-11 MX MX2019014200A patent/MX2019014200A/es unknown
- 2015-09-14 SA SA515361124A patent/SA515361124B1/ar unknown
-
2016
- 2016-06-10 HK HK16106690.2A patent/HK1218727A1/zh unknown
-
2017
- 2017-03-15 US US15/459,093 patent/US9956188B2/en active Active
-
2018
- 2018-02-20 JP JP2018027899A patent/JP2018087231A/ja not_active Withdrawn
- 2018-03-30 US US15/941,484 patent/US10322094B2/en active Active
- 2018-09-24 US US16/140,105 patent/US10864176B2/en active Active
- 2018-09-24 US US16/140,090 patent/US10864175B2/en active Active
-
2019
- 2019-06-03 US US16/429,852 patent/US10736859B2/en active Active
- 2019-08-22 JP JP2019151766A patent/JP2019196407A/ja not_active Withdrawn
-
2020
- 2020-01-14 HR HRP20200055TT patent/HRP20200055T1/hr unknown
- 2020-02-05 CY CY20201100104T patent/CY1122740T1/el unknown
- 2020-10-28 US US17/082,949 patent/US11839594B2/en active Active
- 2020-12-14 US US17/121,547 patent/US11737991B2/en active Active
-
2021
- 2021-06-25 JP JP2021105582A patent/JP2021143208A/ja not_active Withdrawn
-
2023
- 2023-11-02 JP JP2023188486A patent/JP2023181495A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3650081T3 (en) | Eutectic formulations of cyclobenzaprine hydrochloride and mannitol | |
HK1226301A1 (zh) | 修飾的治療劑及其組合物 | |
ZA201602510B (en) | Strigolactone formulations and uses thereof | |
IL277814A (en) | Automatic preparations containing cyclobenzaprine hydrochloride and methods for their preparation | |
HK1221416A1 (zh) | 氧雜雙環庚烷和氧雜雙環庚烯的配製品 | |
HUE045982T2 (hu) | S-Ketamin-hidroklorid gyógyászati kompozíció | |
ZA201507723B (en) | Sustained-release formulations of colchicine and methods of using same | |
HK1218079A1 (zh) | 亞硝酸鹽的藥物製劑及其用途 | |
HK1217670A1 (zh) | 調配物、其製造方法和用途 | |
IL242001B (en) | Sustained-release formulations of colchicine and methods of using same |